InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,464.62
(
-0.16%
)
US TECH 100
19,220.00
(
-0.20%
)
Dow Jones
39,150.33
(
0.04%
)
Brent Oil
84.39
(
0.00%
)
Bitcoin
64,320.56
(
0.12%
)
Post# of 252302
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

iwfal

Send PM Follow Ignore
Followers 75
Posts 4673
Boards Moderated 0
Alias Born 09/06/2003

iwfal

Member Level

Re: mcbio post# 169549

Thursday, 11/07/2013 3:21:43 PM

Thursday, November 07, 2013 3:21:43 PM

Post# of 252302
ARQL -

There is difference in exposure between capsule form used in P2 and tablet form now being used in P3. ... ARQL believes that the exposure of 120mg tablet dose now being used in P3 HCC is similar to range seen in 240mg capsule dose that was used in P2 HCC trial.



While I think caravon is a little too negative (-g-) about the management, that oopsie is pretty bush league and lends support to caravon's view.
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up